NCT05884255 2026-04-17
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Emory University
Sichuan Baili Pharmaceutical Co., Ltd.
Sociedad Española de Medicina Nuclear e Imagen Molecular